Glycyrrhizin ameliorates melanoma cell extravasation into mouse lungs by regulating signal transduction through HMGB1 and its receptors.
epithelial-mesenchymal transition
glycyrrhizin
high mobility group box-1 protein
melanoma
receptor for advanced glycation end product
Journal
Journal of clinical biochemistry and nutrition
ISSN: 0912-0009
Titre abrégé: J Clin Biochem Nutr
Pays: Japan
ID NLM: 8700907
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
07
08
2020
accepted:
01
10
2020
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
12
8
2021
Statut:
ppublish
Résumé
Metastasis, which accounts for the majority of all cancer-related deaths, occurs through several steps, namely, local invasion, intravasation, transport, extravasation, and colonization. Glycyrrhizin has been reported to inhibit pulmonary metastasis in mice inoculated with B16 melanoma. This study aimed to identify the mechanism through which glycyrrhizin ameliorates the extravasation of melanoma cells into mouse lungs. Following B16 melanoma cell injection, mice were orally administered glycyrrhizin once every two days over 2 weeks; lung samples were then obtained and analyzed. Blood samples were collected on the final day, and cytokine plasma levels were determined. We found that glycyrrhizin ameliorated the extravasation of melanoma cells into the lungs and suppressed the plasma levels of interleukin-6, tumor necrosis factor-α, and transforming growth factor-β. Furthermore, glycyrrhizin ameliorated the lung tissue expression of high mobility group box-1 protein (HMGB1), receptor for advanced glycation end products (RAGE), Toll-like receptor (TLR)-4, RAS, extracellular signal-related kinase, NF-κB, myeloid differentiation primary response 88, IκB kinase complex, epithelial-mesenchymal transition markers, and vascular endothelial growth factor-A. Our study demonstrates that glycyrrhizin ameliorates melanoma metastasis by regulating the HMGB1/RAGE and HMGB1/TLR-4 signal transduction pathways.
Identifiants
pubmed: 34376914
doi: 10.3164/jcbn.20-125
pii: DN/JST.JSTAGE/jcbn/20-125
pmc: PMC8325763
doi:
Types de publication
Journal Article
Langues
eng
Pagination
52-60Informations de copyright
Copyright © 2021 JCBN.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest. The glycyrrhizin used by this experiment was supplied from the Cokey Co. free of charge.
Références
EMBO J. 2010 Jul 7;29(13):2242-52
pubmed: 20526283
Cell. 2017 Feb 9;168(4):670-691
pubmed: 28187288
J Cell Biol. 2004 Feb 2;164(3):441-9
pubmed: 14744997
J Biol Chem. 2004 Feb 27;279(9):7370-7
pubmed: 14660645
Cell. 2011 Oct 14;147(2):275-92
pubmed: 22000009
Mol Cell Biochem. 2014 May;390(1-2):271-80
pubmed: 24510323
J Immunol. 2010 Apr 15;184(8):4497-509
pubmed: 20231695
Nat Commun. 2014 Oct 28;5:5256
pubmed: 25348021
Nat Rev Cancer. 2013 Feb;13(2):97-110
pubmed: 23344542
Oncotarget. 2015 Oct 6;6(30):29111-28
pubmed: 26320180
Clin Cancer Res. 2013 Aug 1;19(15):4046-57
pubmed: 23723299
Life Sci. 2001 Oct 5;69(20):2429-38
pubmed: 11681629
Am J Nephrol. 2010;32(6):590-602
pubmed: 21099216
J Cell Mol Med. 2017 Jun;21(6):1046-1057
pubmed: 28039939
PLoS One. 2016 Mar 25;11(3):e0152376
pubmed: 27015414
J Exp Med. 2008 Dec 22;205(13):3007-18
pubmed: 19064698
Exp Cell Res. 2006 Nov 1;312(18):3526-38
pubmed: 16962095
Cell Physiol Biochem. 2016;38(6):2139-51
pubmed: 27184952
Cell Rep. 2018 Jul 24;24(4):962-972
pubmed: 30044991
Mol Cancer. 2019 Jan 18;18(1):12
pubmed: 30657059
J Diabetes Res. 2016;2016:6809703
pubmed: 27547766
Carcinogenesis. 2011 Aug;32(8):1167-75
pubmed: 21642357
Int J Mol Sci. 2018 Aug 16;19(8):
pubmed: 30115883
Mol Immunol. 2013 Dec;56(4):739-44
pubmed: 23954397
Genes Dev. 2013 Oct 15;27(20):2192-206
pubmed: 24142872
Innate Immun. 2018 Nov;24(8):480-489
pubmed: 30246585
Nat Rev Cancer. 2013 Dec;13(12):858-70
pubmed: 24263189
Dig Dis Sci. 2006 Mar;51(3):603-9
pubmed: 16614974
Oncogene. 2014 Apr 3;33(14):1755-63
pubmed: 23604123
Onco Targets Ther. 2018 Jul 04;11:3817-3826
pubmed: 30013362
Int J Cancer. 2015 Oct 1;137(7):1598-609
pubmed: 25821182
Nature. 2000 May 18;405(6784):354-60
pubmed: 10830965
Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):131-40
pubmed: 20123075
Am J Physiol Lung Cell Mol Physiol. 2007 Dec;293(6):L1427-36
pubmed: 17951314
Am J Nephrol. 2015;41(3):257-66
pubmed: 25924590
J Cancer Res Clin Oncol. 2015 Feb;141(2):189-201
pubmed: 24965746
Environ Toxicol. 2018 Dec;33(12):1272-1283
pubmed: 30255981
J Leukoc Biol. 2014 Apr;95(4):563-74
pubmed: 24453275
Autoimmunity. 2009 May;42(4):299-301
pubmed: 19811282
Medicines (Basel). 2019 Jun 22;6(2):
pubmed: 31234488
J Cell Biochem. 2018 Feb;119(2):1922-1930
pubmed: 28815730
J Immunol. 2006 Jan 1;176(1):12-5
pubmed: 16365390
Biosci Biotechnol Biochem. 2007 Aug;71(8):1879-85
pubmed: 17690471
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
Int J Mol Sci. 2017 Aug 19;18(8):
pubmed: 28825631
J Biol Chem. 1995 Oct 27;270(43):25752-61
pubmed: 7592757
Exp Dermatol. 2014 Sep;23(9):659-63
pubmed: 25041031
FASEB J. 2013 Dec;27(12):4731-44
pubmed: 23970797
Annu Rev Immunol. 2010;28:367-88
pubmed: 20192808
Mol Cancer Ther. 2013 Aug;12(8):1676-87
pubmed: 23720768
Cancer Lett. 2017 Apr 10;391:125-140
pubmed: 28131904
Future Med Chem. 2013 Jan;5(1):97-109
pubmed: 23256816
Oncol Rep. 2010 Sep;24(3):693-9
pubmed: 20664975
Oxid Med Cell Longev. 2019 Jan 21;2019:9817576
pubmed: 30805086
Neoplasia. 2009 Jul;11(7):615-28
pubmed: 19568407
Immunol Rev. 2017 Nov;280(1):74-82
pubmed: 29027228
Cancer Lett. 2015 Feb 28;357(2):527-34
pubmed: 25511739
Shock. 2006 Aug;26(2):174-9
pubmed: 16878026
Cell Physiol Biochem. 2017;41(4):1383-1392
pubmed: 28315871
J Invest Dermatol. 1982 Feb;78(2):108-15
pubmed: 7057046
J Immunol. 2012 Mar 1;188(5):2380-6
pubmed: 22287708
Pigment Cell Melanoma Res. 2014 Jan;27(1):19-36
pubmed: 24106873
Chem Biol. 2007 Apr;14(4):431-41
pubmed: 17462578
Anticancer Res. 2002 Nov-Dec;22(6C):4053-8
pubmed: 12553032
Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):20071-6
pubmed: 23169636
Cancer Res. 2012 Jul 1;72(13):3290-301
pubmed: 22552293